Oslo, 12 August 2024: Reference is made to the stock exchange announcement by
Circio Holding ASA (OSE:CRNA) on 9 July 2024 regarding the final result of the
rights issue, raising gross proceeds of NOK 18,107,480. In association with the
rights issue transaction, Atlas guaranteed for NOK 10 million under the existing
convertible bond facility to ensure minimum NOK 19.395 million in gross proceeds
(the "CB commitment"). As the rights issue subscriptions fell below the secured
minimum level, Circio has by a notice of exercise,formally called on the CB
Commitment by requesting Atlas to subscribe and pay for three convertible bonds
with an aggregate principal amount equal to NOK 1,500,000. Atlas will be
allocated these bonds under the terms and conditions of the Investment
Agreement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA gene
therapies and immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.